Study on effect of "Trichosanthis Fructus-Allii Macrostemonis Bulbus" on atherosclerosis in ApoE~(-/-) mice based on liver metabonomics.
10.19540/j.cnki.cjcmm.20210702.403
- Author:
Peng-Bo XU
1
;
Li-Dan DING
1
;
Jing-Wen QIU
1
;
Hua ZHONG
1
;
Huan WU
1
;
An ZHOU
1
;
Hong-Fei WU
1
;
Min DAI
1
Author Information
1. Anhui Province Key Laboratory of Research & Development of Chinese Medicine, Department of Pharmacy, Anhui University of Chinese Medicine Hefei 230012, China.
- Publication Type:Journal Article
- Keywords:
"Trichosanthis Fructus-Allii Macrostemonis Bulbus" drug pari;
ApoE~(-/-) mice;
atherosclerosis;
liver;
metabolomics
- MeSH:
Animals;
Apolipoproteins E/genetics*;
Atherosclerosis/genetics*;
Chromatography, High Pressure Liquid;
Drugs, Chinese Herbal;
Liver;
Metabolomics;
Mice
- From:
China Journal of Chinese Materia Medica
2021;46(20):5320-5329
- CountryChina
- Language:Chinese
-
Abstract:
In this study, ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry(UPLC-Q-TOF-MS)-based liver metabolomics approach was used to explore the mechanism of "Trichosanthis Fructus-Allii Macrostemonis Bulbus" in improving atherosclerosis(AS) of mice with apolipoprotein E gene knockout(ApoE~(-/-)). AS mouse model was induced by high-fat diet. The pathological and biochemical indexes such as the histopathological changes, body weight, liver weight, blood lipid level and inflammatory factors in the liver of mice were determined. The metabolic profiling of mice liver samples was performed with UPLC-Q-TOF-MS. Multiple statistical analysis methods including partial least squares discriminant analysis(PLS-DA) and orthogonal partial least squares discriminant analysis(OPLS-DA) were employed to screen and identify biomarkers. The levels of related enzymes including LCAT, sPLA2, EPT1 and ACER1 were detected. The results showed that "Trichosanthis Fructus-Allii Macrostemonis Bulbus" significantly reduced the areas of aortic plaque and fat vacuoles of liver in AS mice and decreased the accumulation of lipid droplets and liver coefficient. "Trichosanthis Fructus-Allii Macrostemonis Bulbus" also regulated the levels of blood lipid and inflammatory injury in the liver. The metabolites of the control group, the model group and the "Trichosanthis Fructus-Allii Macrostemonis Bulbus" group could be distinguished significantly. Fifteen potential biomarkers related to AS were discovered and preliminarily identified, seven of which could be regulated by "Trichosanthis Fructus-Allii Macrostemonis Bulbus" in a trend of returning to normal. Metabolic pathway analysis screened out two major metabolic pathways. "Trichosanthis Fructus-Allii Macrostemonis Bulbus" obviously regulated the levels of LCAT, sPLA2, EPT1 and ACER1. It was inferred that "Trichosanthis Fructus-Allii Macrostemonis Bulbus" could play a major role in AS treatment by regulating glycerophospholipid and sphingolipid metabolism disorders in the liver, with the mechanism probably relating to the intervention of the expression of LCAT, sPLA2, EPT1 and ACER1.
